US EditionPublished • loading... • Updated
CureGene Unveils Groundbreaking Preclinical Data for CG-0416, a Novel Oral Non-GLP-1 Therapy, at Obesity Week 2025
- CureGene Pharmaceuticals announced groundbreaking preclinical data for CG-0416, a novel oral non-GLP-1 weight-loss agent, at Obesity Week 2025.
- CG-0416 shows high-quality weight loss in diet-induced obese mice, both alone and combined with GLP-1 receptor agonists.
- The combination therapies revealed synergistic effects, demonstrating that CG-0416 with other agents provided greater results than each drug alone.
- CureGene's data confirms CG-0416's potential as a next-generation weight-loss therapy and validates the efficiency of its Jade prodrug technology platform.
Insights by Ground AI
29 Articles
29 Articles
The Berkshire Eagle+28 Reposted by 28 other sources
CureGene Unveils Groundbreaking Preclinical Data for CG-0416, a Novel Oral Non-GLP-1 Therapy, at Obesity Week 2025
CG-0416, a highly liver-targeted THR-β agonist, demonstrates high-quality weight loss by reducing fat mass while preserving muscle, both as a monotherapy and in combination with GLP-1 RAs.
Coverage Details
Total News Sources29
Leaning Left3Leaning Right3Center5Last UpdatedBias Distribution46% Center
Bias Distribution
- 46% of the sources are Center
46% Center
L 27%
C 46%
R 27%
Factuality
To view factuality data please Upgrade to Premium
